WeVote
Log In

Bill

Bill

HR 8890

To amend the Public Health Services Act, commonly referred to as the "Clinical Laboratory Improvement Amendments" or "CLIA", with respect to laboratory developed tests, and for other purposes.

119th Congress Introduced by Neal Dunn

The bill would amend CLIA rules governing laboratory developed tests to change oversight, validation, and reporting requirements for LDTs.

Introduced in House
0
WeVote Research Nonpartisan
Bill Summary · HR 8890

Summary of Bill HR 8890 (119th Congress)

Purpose and intent

  • HR 8890 amends the Public Health Service Act, specifically provisions related to the Clinical Laboratory Improvement Amendments (CLIA), focused on laboratory developed tests (LDTs) and related oversight. The bill’s title indicates a targeted adjustment to CLIA framework with respect to LDTs and other purposes authorized under the act.
  • The general aim appears to address how laboratory developed tests are regulated, evaluated, or implemented within CLIA, potentially altering requirements, oversight, or flexibility for LDTs used in clinical care and diagnostics.

Key provisions and changes (as described by the bill’s scope)

  • The bill makes amendments to the Public Health Service Act focusing on CLIA provisions applicable to LDTs. While the exact statutory text is not provided here, typical changes in such bills may include:
    • Modifications to the regulatory standards applicable to LDTs (e.g., product categorization, validation requirements, performance standards).
    • Changes to the discretion and authority of federal regulatory agencies (such as the Centers for Medicare & Medicaid Services (CMS) under CLIA) over LDTs.
    • Clarifications on who bears responsibility for ensuring analytical validity, clinical validity, and quality control for LDTs.
    • Adjustments to reporting, recordkeeping, or post-market surveillance related to LDTs.
    • Potential alignment with safety, efficacy, or public health objectives tied to laboratory testing.

Note: The exact text would specify which CLIA provisions are amended, the scope of LDTs affected (e.g., in vitro diagnostic tests developed and used within a single laboratory vs. broader commercial deployment), and any transition timelines.

Who would be affected

  • Primary: Clinical laboratories that develop and use laboratory developed tests (LDTs) within the framework of CLIA.
  • Indirectly affected groups may include:
    • Healthcare providers who order LDT-based testing for patient care.
    • Regulatory bodies and CMS administrators responsible for CLIA oversight.
    • Diagnostic developers and laboratories adapting to revised validation, quality, and reporting requirements.
    • Patients who rely on LDTs for diagnostic information, treatment decisions, or disease monitoring, depending on how oversight is tightened or loosened.

Procedural and timeline aspects

  • Action history indicates:
    • Introduced in the U.S. House of Representatives and assigned to committee(s) with jurisdiction over health and tax/appropriations considerations—specifically the Committee on Energy and Commerce and the Committee on Ways and Means.
    • On May 19, 2026, the bill was referred to the Energy and Commerce Committee and to Ways and Means for consideration of provisions falling within their jurisdictions.
  • A sponsor is Neal Dunn (co-sponsor), indicating bipartisan or majority support within related committees, though the details of sponsorship could influence committee action, hearing timing, and potential amendments.
  • No date for floor action or final passage is provided in the current summary.

Potential impacts and considerations

  • Regulatory approach to LDTs could shift toward more stringent validation, clinical performance standards, or post-market monitoring, potentially increasing compliance burden on laboratories.
  • If the bill modifies funding, reporting requirements, or oversight mechanisms, it could affect operational costs for labs and timelines for implementing new testing protocols.
  • Changes could have public health implications by influencing the reliability and accessibility of diagnostic testing, depending on whether the reforms aim to tighten safety or to reduce regulatory obstacles for innovation.

If you’d like, I can pull the exact text of HR 8890 and provide a clause-by-clause analysis of the amendments, along with potential fiscal impacts and timeline projections.

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.